Serbia

Serbia has rapidly emerged as a premier life sciences hub in Southeast Europe, anchored by the ambitious €450 million BIO4 Campus in Belgrade. This multidisciplinary ecosystem integrates biotechnology, biomedicine, bioinformatics and biodiversity, fostering a high-density environment of over 1,000 PhD researchers and 300+ advanced laboratories.

The country is best known for its robust pharmaceutical manufacturing capabilities, with a steady growth trajectory supported by a skilled workforce and strategic proximity to EU markets.

Serbia's healthcare innovation is currently undergoing a massive digital transformation, prioritizing e-health solutions, integrated electronic health records and AI-driven diagnostics.

The medical device sector is expanding through increased foreign direct investment (FDI), as global companies leverage local cost-efficiencies and technical expertise for R&D and specialized production.

Academic research in Serbia is world-class, led by the University of Belgrade and specialized institutes like the IMGGE, which excel in molecular genetics and genome analysis.

With a strong emphasis on precision medicine and clinical trials, the region offers a fertile ground for biotech startups and global pharma partnerships.

Serbia also positions itself as a leader in data science applications within healthcare, bridging the gap between traditional medicine and cutting-edge healthtech.

This thriving ecosystem is supported by a favorable regulatory environment and a strategic focus on biomanufacturing sovereignty.

Ultimately, Serbia provides a unique value proposition for global stakeholders seeking innovation-driven growth and high-quality scientific collaboration in the heart of the Balkans.